Towards a molecular classification of colorectal cancer: The role of BRAF
Frontiers in Oncology, 2013 Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis.
Alexandra eThiel, Ari eRistimäki
doaj +1 more source
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. [PDF]
, 2017 Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation.
Chmielowski, Bartosz +16 more
core +1 more source
BRAF mutation in hairy cell leukemia
Oncology Reviews, 2014 BRAF is a serine/threonine kinase with a regulatory role in the mitogen-activated protein kinase (MAPK) signaling pathway. A mutation in the RAF gene, especially in BRAF protein, leads to an increased stimulation of this cascade, causing uncontrolled cell division and development of malignancy.
Ahmad Ahmadzadeh +7 more
openaire +3 more sources
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. [PDF]
, 2017 BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies.
Ahuja, Amit +4 more
core +2 more sources
International Journal of General Medicine, 2021 Linjue Shangguan,1,* Peipei Zhang,1 Shengwei Fang,1 Kaili Xiang,1 Yawen Geng,1 Dingcun Luo,2,* Chunlei Zhao1,* 1Department of Nuclear Medicine, Hangzhou Cancer Hospital, Hangzhou, 310002, People’s Republic of China; 2Department of Tumor ...
Shangguan L +6 more
doaj
JTO Clinical and Research Reports, 2020 Introduction: There is no consensus on whether immune checkpoint inhibitors (ICIs) would offer comparable benefit in mutant-BRAF NSCLC. We, therefore, conducted a study to ascertain the role of ICIs in mutant-BRAF NSCLC. Methods: Records of 4178 patients
Chenxing Zhang, PhD +4 more
doaj +1 more source
Metastases risk in thin cutaneous melanoma: Prognostic value of clinical-pathologic characteristics and mutation profile [PDF]
, 2018 Background: A high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases.
Calvieri, Stefano +12 more
core +1 more source
BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
PLoS ONE, 2020 BackgroundPapillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm comprising 80-90% of all thyroid malignancies. Molecular changes in thyroid follicular cells are likely associated with the development of PTC.
Suhail Al-Salam +6 more
doaj +1 more source
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol +5 more
core +2 more sources
BRAF Mutation in Papillary Thyroid Carcinoma [PDF]
JNCI Journal of the National Cancer Institute, 2003 The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In
Yoram, Cohen +9 more
openaire +2 more sources